NCT01367080CompletedPhase 1
Clinical Trials to Compare the Pharmacokinetics Profile of Etravil®(Amitriptyline Hydrochloride) Tablet 10mg and Etravil®(Amitriptyline Hydrochloride) Tablet 25mg After a Single Oral Administration in Healthy Male Volunteers
Dong Wha Pharmaceutical Co. Ltd.1 site in 1 country12 target enrollmentStarted: July 2011Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 12
- Locations
- 1
- Primary Endpoint
- AUClast and AUCinf
Study Overview
Brief Summary
To evaluate the pharmacokinetics of single oral dose of Amitriptyline hydrochloride film-coated tablet 10mg & 25mg
Detailed Description
Randomized, Single dose, 2-way crossover, Open Study to compare the pharmacokinetics profile of Etravil®(Amitriptyline Hydrochloride) Tablet 10mg and Etravil®(Amitriptyline Hydrochloride) Tablet 25mg after a single oral administration in healthy male volunteers
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Basic Science
- Masking
- None
Eligibility Criteria
- Ages
- 19 Years to 50 Years (Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •a healthy adult male within the range of 19 to 50 years old at the time of screening
- •one with weight of more than 55kg, in the range of IBW 20%
- •Ideal Body Weight(IBW)(kg)={height(cm)-100}*0.9
- •one who understood completely about this study after the detailed explanation is given, decided to volunteer and gave written informed consent to participate in study in compliance with the requirement of the entire protocol.
Exclusion Criteria
- •one with clinically significant disease in liver, kidney, nerve system, respiratory system, endocrine system, blood, tumor, urinary system, cardiovascular system, mental disease or with medical history
- •one with glaucoma
- •one with disorders of micturition include benign prostatic hyperplasia
- •one with gastrointestinal disease or with gastrointestinal surgical history which can affect the absorption of the investigational drug.
- •one who is allergic or has clinically significant allergic history to the study drug, components or tricyclic antidepressants(TCA)
- •one who shows the following result in vital sign: hypotension(systolic pressure ≤ 100mmHg or diastolic pressure ≤ 65mmHg) or hypertension(systolic pressure ≥ 150mmHg or diastolic pressure ≥ 95mmHg)
- •one who has drug abuse history
- •one who has taken any prescribed drugs, herbal agents or crude drugs within 2 weeks before study drug administration, or who has taken any over-the-counter (OTC) drugs or vitamins (Investigators will determine his eligibility by considering the effect of the drug on his safety or pharmacokinetic results in case other inclusion/exclusion criteria is satisfied.)
- •one who has participated in other clinical study within 2 months before study drug administration
- •one who donated whole blood within 2 months or component blood within 1 month or who are donated within 1 month before the treatment
- •one who drank Over 21 units/week of alcohol(1 unit = 10g of pure alcohol) or subjects who would not be able to stop drinking alcohol during the hospitalization
- •one who are heavy smoker more than 10 cigarettes/day within 3 months prior to screening or subjects who would not be able to stop smoking during the hospitalization
- •one who had a beverage containing caffeine, drank alcohol, or smoked within 48hrs before the hospitalization or who had a beverage containing grapefruits during the hospitalization
- •one with clinically significant observations considered as unsuitable based on medical judgment by investigators
Arms & Interventions
A Group
Experimental
- 1st administration - DWETR10
- 2nd administration - DWETR25
Intervention: DWETR10 (Drug)
A Group
Experimental
- 1st administration - DWETR10
- 2nd administration - DWETR25
Intervention: DWETR25 (Drug)
B Group
Experimental
- 1st administration - DWETR25
- 2nd administration - DWETR10
Intervention: DWETR10 (Drug)
B Group
Experimental
- 1st administration - DWETR25
- 2nd administration - DWETR10
Intervention: DWETR25 (Drug)
Outcomes
Primary Outcomes
AUClast and AUCinf
Time Frame: Up to 72 hours
Area Under the Plasma concentration-time curve from time Zero to Infinity(AUCinf) and Area Under the Plasma concentration-time curve from time Zero to last time(AUClast) of Amitryptiline in plasma
Secondary Outcomes
- Tmax(Up to 72 hours)
- Cmax(Up to 72 hours)
- t1/2(Up to 72 hours)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Compare the Pharmacokinetics of TAH(80/10/12.5) Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male VolunteersHealthyNCT03032315IlDong Pharmaceutical Co Ltd44
Completed
Phase 1
Assessment of the Pharmacokinetics of a Sustained Release Formulation of a Tramadol/Acetaminophen CombinationPainNCT01880125Yungjin Pharm. Co., Ltd.24
Completed
Phase 1
A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Renal Impairment Patients and Healthy VolunteersRenal ImpairmentNCT01148368Boryung Pharmaceutical Co., Ltd16
Completed
Phase 1
Clinical Trial to Compare the Pharmacokinetics and Pharmacodynamics After Oral Administration of Glucophage and HL-018HealthyNCT01232036Asan Medical Center28
Completed
Phase 1
A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic FunctionModerate Hepatic ImpairmentNCT05610657Agios Pharmaceuticals, Inc.20